Epigenetic regulatory networks in the pathogenesis and treatment of osteoporosis subtypes.
5 affiliations
- 1Division of Spine Surgery, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
- 2Department of Biomedical Engineering, The Hong Kong Polytechnic University, Hong Kong, 999077, China.
- 3Department of Cardiology, Laboratory of Heart Center, Translational Medicine Research Center, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510282, China. [email protected].
- 4Division of Spine Surgery, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. [email protected].
- 5Department of Joint and Orthopedics, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, 510282, China. [email protected].
Abstract
Osteoporosis is a systemic skeletal disorder characterized by reduced bone mineral density and heightened bone fragility, encompassing primary (senile and postmenopausal) and secondary (glucocorticoid-induced and diabetic) subtypes. Maintaining skeletal health relies on the dynamic balance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption. Among the multitude of factors orchestrating this bone remodeling process, epigenetics, which regulates gene expression via reversible chemical modifications without altering the primary DNA sequence, plays an essential role in maintaining bone homeostasis. While previous research has identified numerous epigenetic factors in bone metabolism, a comprehensive synthesis of their specific contributions to different osteoporosis subtypes and the corresponding therapeutic strategies remains lacking. This review outlines the major epigenetic mechanisms involved in bone metabolism, including DNA methylation, histone modifications, RNA modifications, and non-coding RNAs. Subsequently, we comprehensively elucidate how the dysregulation of these epigenetic landscapes drives the pathogenesis of distinct osteoporosis subtypes, emphasizing their roles in disrupting the osteoblast-osteoclast axis. Furthermore, we review emerging epigenetic-based therapeutics across distinct osteoporosis subtypes, ranging from systemic pharmacological inhibitors, such as DNA methyltransferase and histone demethylase inhibitors, to advanced delivery platforms targeting the skeletal microenvironment, such as engineered extracellular vesicles and functionalized nanocarriers. By integrating molecular mechanistic insights with these diverse therapeutic strategies, this review establishes a comprehensive framework for understanding the epigenetic heterogeneity in the pathogenesis and therapeutics of osteoporosis. Ultimately, it provides essential directions for future investigations, offering innovative epigenetic strategies to tackle various osteoporosis subtypes.
Related
- The Cx43/p38 MAPK/Runx2 signaling pathway as a potential regulatory axis in insufficient osteogenesis associated with osteoporosis
- Osteoporosis treatment via programmed delivery of IRF5 siRNA to macrophages in bone tissue combined with ROS scavenging.
- Spatiotemporal Multi-Omics and Compartment-Resolved Metabolomic Analyses Reveal the Mechanisms and Core Regulatory Networks of Cuticular Wax Formation in Blueberry Fruits
- Dynamic three-dimensional chromatin remodeling in lung disease: mechanistic principles, pathogenic regulatory networks, and translational challenges
- Multiplex navigation of global regulatory networks (MINR) in yeast for improved ethanol tolerance and production
BibTeX
@article{ren2026epigenetic,
title = {{Epigenetic regulatory networks in the pathogenesis and treatment of osteoporosis subtypes.}},
author = {Zhengda Ren and Bingyang Dai and Dequan Chen and Zehui Li and Keyu Meng and Shanwei Lan and Canzhao Liu and Zhongmin Zhang and Xiaoyi Mo},
journal = {Molecular biomedicine},
year = {2026},
month = oct,
doi = {10.1186/s43556-026-00630-1},
url = {https://europepmc.org/article/MED/42905228},
note = {CC BY},
}
RIS
TY - JOUR
TI - Epigenetic regulatory networks in the pathogenesis and treatment of osteoporosis subtypes.
AU - Zhengda Ren
AU - Bingyang Dai
AU - Dequan Chen
AU - Zehui Li
AU - Keyu Meng
AU - Shanwei Lan
AU - Canzhao Liu
AU - Zhongmin Zhang
AU - Xiaoyi Mo
PY - 2026
DA - 2026/10/21
JO - Molecular biomedicine
DO - 10.1186/s43556-026-00630-1
UR - https://europepmc.org/article/MED/42905228
AB - Osteoporosis is a systemic skeletal disorder characterized by reduced bone mineral density and heightened bone fragility, encompassing primary (senile and postmenopausal) and secondary (glucocorticoid-induced and diabetic) subtypes. Maintaining skeletal health relies on the dynamic balance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption. Among the multitude of factors orchestrating this bone remodeling process, epigenetics, which regulates gene expression via reversible chemical modifications without altering the primary DNA sequence, plays an essential role in maintaining bone homeostasis. While previous research has identified numerous epigenetic factors in bone metabolism, a comprehensive synthesis of their specific contributions to different osteoporosis subtypes and the corresponding therapeutic strategies remains lacking. This review outlines the major epigenetic mechanisms involved in bone metabolism, including DNA methylation, histone modifications, RNA modifications, and non-coding RNAs. Subsequently, we comprehensively elucidate how the dysregulation of these epigenetic landscapes drives the pathogenesis of distinct osteoporosis subtypes, emphasizing their roles in disrupting the osteoblast-osteoclast axis. Furthermore, we review emerging epigenetic-based therapeutics across distinct osteoporosis subtypes, ranging from systemic pharmacological inhibitors, such as DNA methyltransferase and histone demethylase inhibitors, to advanced delivery platforms targeting the skeletal microenvironment, such as engineered extracellular vesicles and functionalized nanocarriers. By integrating molecular mechanistic insights with these diverse therapeutic strategies, this review establishes a comprehensive framework for understanding the epigenetic heterogeneity in the pathogenesis and therapeutics of osteoporosis. Ultimately, it provides essential directions for future investigations, offering innovative epigenetic strategies to tackle various osteoporosis subtypes.
SN - 2662-8651
ER -